Lung cancer trials in Germany

In Germany 182 Also abroad 2733

182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Chemnitz, Gauting, Goettingen, Immenstadt I. Allgäu, Munich
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Giessen, Goettingen, Heidelberg, Immenhausen, Köln, Luebeck, Munich
Age
18 years and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
Phase 2Taking people
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Where
Chemnitz, Essen, Esslingen am Neckar, Munich
Age
18 years and over
People
105 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg, Hanover, Heidelberg, Homburg, Immenhausen, Karlsruhe, Löwenstein, Lübeck, Mannheim, München, Münster, Oldenburg, Regensburg, Tübingen, Würzburg
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Bad Berka, Berlin, Bonn, Essen, Frankfurt am Main, Gauting, Giessen, Grosshansdorf, Heidelberg, Homburg, Hösbach, Immenhausen, Jena, Kassel, Koblenz, Luebeck, Moers, Stuttgart
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Augsburg, Berlin, Gauting, Goettingen, Grosshansdorf, Halle (saale), Immenhausen, Jena, Koblenz, Ludwigshafen Am Rhein, Luebeck, Regensburg
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 1/2Taking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Cologne, Essen, Frankfurt Am Main, Heidelberg, Oldenburg
Age
18 years and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte, Gera, Grosshansdorf, Halle (Saale), Hamburg, Heidelberg, Kiel, Muenster, Nuremberg, Tuebingen
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Berlin, Cologne, Essen, Frankfurt Am Main, Giessen, Hemer, Nuremberg, Stuttgart
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Berlin, Chemnitz, Cologne, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf, Halle, Hamburg, Heidelberg, Hemer, Herne, Leipzig, Nuremberg, Stuttgart, Tübingen
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Hamburg, Heidelberg, Leipzig, Mainz, München, Würzburg
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 3Taking people
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Where
Berlin, Gauting, Georgsmarienhuette, Heidelberg, Mainz, Oldenburg
Age
18 years and over
People
65 worldwide
Run by
Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00 · EU 2022-502959-54-00
Phase 2Taking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Cologne, Grosshansdorf, Immenhausen, Wuerzburg
Age
18 years and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Berlin, Gera, Grosshansdorf, Hanover, Mainz, Marburg, Moers, Muenster, Munich, Ravensburg
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 1/2Taking people
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Where
Berlin, Cologne, Dresden, Heidelberg
Age
18 years and over
People
334 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01
Phase 2Taking people
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Greifswald, Leipzig, Munich, Stuttgart
Age
18 years and over
People
480 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00
No phaseTaking people
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Where
Aschaffenburg, Bielefeld, Bochum, Bremen, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg, Hanover, Hemer, Konstanz, Landshut, Neuss, Recklinghausen, Solingen, Stolberg, Ulm
Age
18 years and over
People
380 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07230691
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Berlin, Cologne, Essen, Giessen, Halle (saale), Hanover, Heidelberg, Mannheim
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 2/3Taking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Berlin, Dresden, Hamburg, Mannheim
Age
18 years and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Aachen, Augsburg, Berlin, Bonn, Chemnitz, Duesseldorf, Erlangen, Esslingen am Neckar, Frankfurt am Main, Gauting, Gera, Giessen, Halle (Saale), Hamburg, Hanover, Heidelberg, Immenhausen Hesse, Koblenz, Mainz, Moers, Muenster, Munich, Neuss, Oldenburg, Remscheid, Rostock, St. Juergen Luebeck, Tuebingen, Wuppertal
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 3Taking people
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Where
Amberg, Berlin, Cologne, Esslingen am Neckar, Gauting, Ravensburg
Age
18 years to 90 years
People
507 worldwide
Run by
ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Berlin, Cologne, Esslingen am Neckar, Frankfurt Am Main, Gauting, Grosshansdorf, Heidelberg, Oldenburg, Wuerzburg
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Amberg, Augsburg, Bad Homburg, Brunswick, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt am Main, Giessen, Grosshansdorf, Hamburg, Hanover, Hemer, Immenstadt I. Allgäu, Kaiserslautern, Kassel, Kempten (Allgau), Krefeld, Loewenstein, Luebeck, Moenchengladbach, Munich, Neuruppin, Offenbach Am Main, Trier, Ulm
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1/2Taking people
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Where
Berlin, Dresden, Frankfurt Am Main, Munich
Age
18 years and over
People
345 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00
No phaseTaking people
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Where
Erlangen
Age
3 years and over
People
180
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07705178